Due to its array of radiographic patterns, interstitial lung disease can be challenging to diagnose and treat. Adam Guttentag, MD, a cardiothoracic radiologist, shared tips for ordering and interpreting chest computed tomography.
Transformational Teaching: How to Be a Highly Effective Medical Educator
Jonathan Hausmann, MD, discussed how active learning techniques, such as the flipped classroom, can increase the effectiveness of medical education and the success of rheumatology fellows.
Updates from the ACR’s Committee on Rheumatology Training & Workforce Issues
The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.
PsA Trial Design Can Improve Patient Safety, Outcomes
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
How to Recognize an Autoinflammatory Disorder
Autoinflammatory disorders may involve genetic mutations of the inflammasome or an environmental trigger in a genetically susceptible host. Dr. Jay Mehta discussed a practical, clinical approach to caring for patients with autoinflammatory disorders, such as periodic fever syndromes, during the 2022 ACR Education Exchange.
Pearls of Wisdom: Innovations in Teaching Shared at the 2022 ACR Education Exchange
Experts presented ways to rethink journal club to improve engagement and how an image-based program can help teach the assessment of cutaneous lupus erythematosus across differing skin tones.
Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising
In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.
Medication Preferences & Current Practices for PsA
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Pre-Eclampsia Risk & Rheumatic Disease
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 91
- Next Page »